# A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Source: https://onco.cc/trials/quintessential-2/  
OnCo record `quintessential-2` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Arlocabtagene Autoleucel in multiple myeloma, now recruiting.

## Summary

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) is a phase 3 interventional study registered as NCT06615479, led by Juno Therapeutics, a Bristol-Myers Squibb with Celgene, and recruiting on the registry. Official title: A Phase 3, Randomised, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma. Planned enrolment is 440 participants (estimated). The study started in 2025-03-12 and primary completion is expected in 2027-12-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: QUINTESSENTIAL-2
- Tags: ctgov-ingest
- Registry id: NCT06615479
- Phase: 3
- Setting: A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma
- Sponsor: Juno Therapeutics, a Bristol-Myers Squibb
- Enrolled: 440

## Sources

- ClinicalTrials.gov NCT06615479: https://clinicaltrials.gov/study/NCT06615479

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- drugs: [Arlocabtagene Autoleucel](https://onco.cc/drugs/arlocabtagene-autoleucel/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/quintessential-2.json